Authors/Disclosures
|
Zongqi Xia, MD, PhD
|
Dr. Xia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Xia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. The institution of Dr. Xia has received research support from National Institute of Health. The institution of Dr. Xia has received research support from Octave Biosciences. The institution of Dr. Xia has received research support from Department of Defense. The institution of Dr. Xia has received research support from Genentech/Roche. |
|
Lori Chibnik
|
No disclosure on file |
|
Joshua M. Shulman, MD, PhD, FAAN
(Duncan Neurological Research Institute)
|
Dr. Shulman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Shulman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Helis Medical Foudation. The institution of Dr. Shulman has received research support from National Institutes of Health. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Bonnie Glanz
(Brigham and Women'S Hospital)
|
The institution of Ms. Glanz has received research support from CMSC. The institution of Ms. Glanz has received research support from NIH. |
|
Charles R. Guttmann
|
Charles R.G. Guttmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica SA. Charles R.G. Guttmann has received stock or an ownership interest from Alnylam. Charles R.G. Guttmann has received stock or an ownership interest from Roche. Charles R.G. Guttmann has received stock or an ownership interest from Novartis. Charles R.G. Guttmann has received stock or an ownership interest from Arrowhead Pharmaceuticals. Charles R.G. Guttmann has received stock or an ownership interest from Protalix. Charles R.G. Guttmann has received stock or an ownership interest from Promethee. Charles R.G. Guttmann has received stock or an ownership interest from GSK. Charles R.G. Guttmann has received stock or an ownership interest from Sangamo. Charles R.G. Guttmann has received stock or an ownership interest from Alcon. Charles R.G. Guttmann has received stock or an ownership interest from Cocrystal Pharma. The institution of Charles R.G. Guttmann has received research support from NIH. The institution of Charles R.G. Guttmann has received research support from McGill University. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from BrightFocus Foundation. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from University of Connecticut Health Center. The institution of Charles R.G. Guttmann has received research support from U.S. Office of Naval Research. |
|
Samia J. Khoury, MD, FAAN
(Nehme and Therese Tohme MS Center)
|
Dr. Khoury has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merk. Dr. Khoury has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Khoury has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ANA. Dr. Khoury has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Clinical Immunology. The institution of Dr. Khoury has received research support from MENACTRIMS. The institution of Dr. Khoury has received research support from NMSS. The institution of Dr. Khoury has received research support from Office of Naval Research USA. An immediate family member of Dr. Khoury has received intellectual property interests from a discovery or technology relating to health care. |
|
Tanuja Chitnis, MD, FAAN
(Brigham and Women's Hospital)
|
Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Siemens. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. |
|
Howard L. Weiner, MD
(Brigham and Women'S Hospital)
|
Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc.. |
|
Philip De Jager, MD, PhD
(Columbia University Irving Medical Center)
|
Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from Biogen. The institution of Dr. De Jager has received research support from puretech. |
|
Felipe De Los Rios La Rosa, MD
(Miami Neuroscience Institute)
|
Dr. De Los Rios La Rosa has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. |